GlassScriptPhysician profile
Alan Shay Davis
NPI 1528008265
$1,361.51
in general payments reported to CMS, 2019-2025
20 companies · $528 in 2025
The $528 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.39 · 2020: $14.17 · 2021: $153 · 2022: $145 · 2023: $161 · 2024: $285 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $245.64 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $154.59 | 2024 | |
| Organon LLC | $135.77 | 2022-2025 | Nexplanon |
| Pfizer INC. | $114.49 | 2019-2024 | |
| Daiichi Sankyo INC. | $86.24 | 2021-2024 | Injectafer |
| Abbvie INC. | $77.99 | 2021-2022 | |
| Coopersurgical, INC. | $72.97 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Exact Sciences Corporation | $71.97 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $69.98 | 2023-2025 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $66.52 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $60.04 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $45.76 | 2019-2025 | |
| Hologic Sales and Service, LLC | $31.27 | 2019-2022 | |
| Agile Therapeutics, INC. | $28.80 | 2023-2024 | Twirla |
| Allergan, INC. | $24.45 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $23.26 | 2023 | Slynd |
| Seqirus USA INC | $22.43 | 2025 | Fluad, Flucelvax |
| Medtronic, INC. | $15.19 | 2024 | Interstim |
| Novo Nordisk INC | $14.15 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.